IFRX
InflaRxยทNASDAQ
--
--(--)
--
--(--)
IFRX Profile
Inflarx N.V.
A clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system
Winzerlaer Str. 2, 07745 Jena, Germany
--
InflaRx N.V., formerly known as Fireman B.V., was incorporated under the laws of the Netherlands in June 2017 and is the holding company of InflaRx GmbH. The change was made in accordance with the terms of the company's reorganization. InflaRx is a biopharmaceutical company that utilizes its proprietary technology to discover, develop and commercialize inhibitors of complement activator C5a and its receptor C5aR. The company is committed to efficiently and selectively modulating the C5a/C5aR axis to inhibit the inflammatory response associated with complement activation, and to develop drug candidates for C5a-mediated inflammation-related diseases.
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
